Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries....
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324000146 |
| _version_ | 1797249068347424768 |
|---|---|
| author | Yuki Katayama, MD, PhD Tadaaki Yamada, MD, PhD Kenji Morimoto, MD, PhD Hiroyuki Fujii, MD Satomi Morita, MD, PhD Keiko Tanimura, MD, PhD Takayuki Takeda, MD, PhD Asuka Okada, MD, PhD Shinsuke Shiotsu, MD, PhD Yusuke Chihara, MD, PhD Osamu Hiranuma, MD Takahiro Yamada, MD, PhD Takahiro Ota, MD, PhD Taishi Harada, MD Isao Hasegawa, MD, PhD Masahiro Iwasaku, MD, PhD Shinsaku Tokuda, MD, PhD Noriyuki Tanaka, MD, PhD Aya Miyagawa-Hayashino, MD, PhD Koichi Takayama, MD, PhD |
| author_facet | Yuki Katayama, MD, PhD Tadaaki Yamada, MD, PhD Kenji Morimoto, MD, PhD Hiroyuki Fujii, MD Satomi Morita, MD, PhD Keiko Tanimura, MD, PhD Takayuki Takeda, MD, PhD Asuka Okada, MD, PhD Shinsuke Shiotsu, MD, PhD Yusuke Chihara, MD, PhD Osamu Hiranuma, MD Takahiro Yamada, MD, PhD Takahiro Ota, MD, PhD Taishi Harada, MD Isao Hasegawa, MD, PhD Masahiro Iwasaku, MD, PhD Shinsaku Tokuda, MD, PhD Noriyuki Tanaka, MD, PhD Aya Miyagawa-Hayashino, MD, PhD Koichi Takayama, MD, PhD |
| author_sort | Yuki Katayama, MD, PhD |
| collection | DOAJ |
| description | Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear. Methods: In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients. Results: The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival. Conclusions: In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958. |
| first_indexed | 2024-03-07T16:52:54Z |
| format | Article |
| id | doaj.art-3964141379334812bbe15faf7291e902 |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-04-24T20:24:36Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-3964141379334812bbe15faf7291e9022024-03-22T05:40:44ZengElsevierJTO Clinical and Research Reports2666-36432024-03-0153100644Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective StudyYuki Katayama, MD, PhD0Tadaaki Yamada, MD, PhD1Kenji Morimoto, MD, PhD2Hiroyuki Fujii, MD3Satomi Morita, MD, PhD4Keiko Tanimura, MD, PhD5Takayuki Takeda, MD, PhD6Asuka Okada, MD, PhD7Shinsuke Shiotsu, MD, PhD8Yusuke Chihara, MD, PhD9Osamu Hiranuma, MD10Takahiro Yamada, MD, PhD11Takahiro Ota, MD, PhD12Taishi Harada, MD13Isao Hasegawa, MD, PhD14Masahiro Iwasaku, MD, PhD15Shinsaku Tokuda, MD, PhD16Noriyuki Tanaka, MD, PhD17Aya Miyagawa-Hayashino, MD, PhD18Koichi Takayama, MD, PhD19Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Corresponding author. Address for correspondence: Tadaaki Yamada, MD, PhD, Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, JapanDepartment of Respiratory Medicine, Saiseikai Suita Hospital, Osaka, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, JapanDepartment of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, JapanDepartment of Respiratory Medicine, Otsu City Hospital, Shiga, JapanDepartment of Respiratory Medicine, Matsushita Memorial Hospital, Osaka, JapanDepartment of Respiratory Medicine, Kyoto city Hospital, Kyoto, JapanDepartment of Medical Oncology, Fukuchiyama City Hospital, Kyoto, JapanDepartment of Respiratory Medicine, Saiseikai Shigaken Hospital, Shiga, JapanDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Pathology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Pathology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanIntroduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear. Methods: In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients. Results: The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival. Conclusions: In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.http://www.sciencedirect.com/science/article/pii/S2666364324000146ChemoimmunotherapyPD-L1Non–small cell lung cancerProspective analysisTherapeutic response |
| spellingShingle | Yuki Katayama, MD, PhD Tadaaki Yamada, MD, PhD Kenji Morimoto, MD, PhD Hiroyuki Fujii, MD Satomi Morita, MD, PhD Keiko Tanimura, MD, PhD Takayuki Takeda, MD, PhD Asuka Okada, MD, PhD Shinsuke Shiotsu, MD, PhD Yusuke Chihara, MD, PhD Osamu Hiranuma, MD Takahiro Yamada, MD, PhD Takahiro Ota, MD, PhD Taishi Harada, MD Isao Hasegawa, MD, PhD Masahiro Iwasaku, MD, PhD Shinsaku Tokuda, MD, PhD Noriyuki Tanaka, MD, PhD Aya Miyagawa-Hayashino, MD, PhD Koichi Takayama, MD, PhD Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study JTO Clinical and Research Reports Chemoimmunotherapy PD-L1 Non–small cell lung cancer Prospective analysis Therapeutic response |
| title | Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study |
| title_full | Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study |
| title_fullStr | Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study |
| title_full_unstemmed | Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study |
| title_short | Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study |
| title_sort | comparing three different anti programmed death ligand 1 antibodies in immunohistochemical evaluation of combined chemoimmunotherapy response in patients with nsclc a prospective study |
| topic | Chemoimmunotherapy PD-L1 Non–small cell lung cancer Prospective analysis Therapeutic response |
| url | http://www.sciencedirect.com/science/article/pii/S2666364324000146 |
| work_keys_str_mv | AT yukikatayamamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT tadaakiyamadamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT kenjimorimotomdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT hiroyukifujiimd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT satomimoritamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT keikotanimuramdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT takayukitakedamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT asukaokadamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT shinsukeshiotsumdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT yusukechiharamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT osamuhiranumamd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT takahiroyamadamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT takahirootamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT taishiharadamd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT isaohasegawamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT masahiroiwasakumdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT shinsakutokudamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT noriyukitanakamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT ayamiyagawahayashinomdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy AT koichitakayamamdphd comparingthreedifferentantiprogrammeddeathligand1antibodiesinimmunohistochemicalevaluationofcombinedchemoimmunotherapyresponseinpatientswithnsclcaprospectivestudy |